Supernus Pharma (SUPN) Misses Q2 EPS

Supernus Pharma (NASDAQ: SUPN) reported Q2 GAAP EPS of ($0.02), which may not compare to the analyst estimate of $0.22. Revenue for the quarter came in at $135.56 million versus the consensus estimate of $144.53 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c